Disease Overview：Cardiorenal Syndrome（CRS）
Cardio-Renal Syndrome (CRS) is a pathophysiologic disorder characterized by bidirectional dysfunction between the heart and kidneys, where acute or chronic impairment in one organ induces acute or chronic dysfunction in the other. Classified into five subtypes (Type 1–5) based on temporal sequence and underlying mechanisms—such as acute decompensated heart failure triggering acute kidney injury (Type 1), or chronic kidney disease exacerbating left ventricular hypertrophy and diastolic dysfunction (Type 4)—CRS demands integrated, multidisciplinary management. Diagnosis relies on comprehensive assessment including echocardiography, NT-proBNP, serum creatinine, cystatin C, urinary NGAL, and advanced imaging like cardiac MRI or renal Doppler ultrasound. Treatment targets hemodynamic optimization, neurohormonal modulation (e.g., RAAS inhibitors, SGLT2 inhibitors), volume control, and, when indicated, device-based interventions such as ultrafiltration or CRT-D implantation. Prognosis remains guarded without timely, coordinated care across cardiology and nephrology disciplines.
China offers distinct advantages for CRS management: leading tertiary hospitals—such as Peking University First Hospital and Shanghai Renji Hospital—host nationally accredited Cardio-Renal Centers staffed by dual-certified cardiorenal specialists. These centers utilize cutting-edge technologies including real-time intrarenal Doppler monitoring, AI-driven eGFR trajectory modeling, and hybrid cardiac-kidney rehabilitation protocols. Clinical outcomes reflect this integration: published cohort studies report 32% lower 1-year rehospitalization rates for CRS Type 2 patients managed in China versus Western benchmarks. Costs remain highly competitive—comprehensive diagnostic workup and 3-month targeted therapy average USD 12,000–18,000, roughly 40–60% less than equivalent care in the US or Germany, with no compromise in evidence-based protocol adherence. As a dedicated medical tourism agency, we facilitate seamless access to these resources: verifying hospital accreditation, coordinating specialist consultations, providing itemized, upfront pricing in USD, arranging visa support, translation services, and post-treatment follow-up—all tailored to international patients’ clinical and logistical needs.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Cardiorenal Syndrome (Nephrology Department)
Non-Surgical / Conservative / Medication Management
*Target Criteria:* Stage 1–3 CRS (acute decompensated HF with worsening renal function, eGFR ≥30 mL/min/1.73m²; no refractory volume overload or cardiogenic shock).
- •Core Pharmacotherapy (30-day supply):
- RAAS inhibitors (valsartan or sacubitril/valsartan): $45–$110 - SGLT2 inhibitors (dapagliflozin): $68–$92 - Beta-blockers (bisoprolol): $8–$22
- •Essential Monitoring (per cycle):
- Comprehensive metabolic panel (electrolytes, creatinine, urea): $18 - Urine albumin-to-creatinine ratio (UACR): $15 - Echocardiogram (TTE): $72 - Daily nursing + fluid balance charting: $36/day
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Refractory CRS Type 1 or 2 (eGFR <30 mL/min/1.73m², persistent congestion despite max-tolerated meds, LVEF ≤35%, no contraindications to device therapy or dialysis).
- •Ultrafiltration (Aquapheresis) – Single session:
- Procedure + disposables + nursing: $320–$490
- •Temporary Hemodialysis (CVVHDF or IHD) – Per session:
- Session (4–6 hrs, anticoagulation, monitoring): $260–$380
- •Implantable Hemodynamic Monitor (e.g., CardioMEMS™):
- Device implant + fluoroscopy + programming: $4,200–$5,100
Special / Complex Condition Management
- •CRS Type 5 (sepsis-associated):
- Continuous renal replacement therapy (CRRT) – 24-hr cycle: $680–$890
- •End-stage CRS with dialysis-dependent CKD + HFrEF:
- Palliative nephrology consultation (symptom-focused care): $145/session
Quick Selection Guide
- •<65 years, eGFR ≥45, mild congestion, budget <$500/month: Start with SGLT2i + low-dose diuretic + monthly UACR/eGFR monitoring ($185–$290/month).
- •65–80 years, eGFR 25–44, recurrent hospitalizations, moderate budget ($1,000–$2,500): Add ultrafiltration for acute decongestion + RAASi titration ($420–$620/session).
- •>80 years, eGFR <20, frailty, multiple comorbidities, limited life expectancy: Prioritize palliative nephrology + symptom-directed diuretic management ($145–$220/visit).
- •Acute cardiogenic shock + AKI (CRS Type 1): Immediate CRRT + right heart catheterization ($1,100–$1,400 first 48 hrs).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Cardiorenal Syndrome Medical Vacation Packages
Curated transparent all-inclusive packages combining Cardiorenal Syndrome treatment with China top medical destinations:
